Research progress on evaluation indexes and application of evaluation tools for postoperative intestinal intolerance in patients
with esophageal cancer
Esophageal cancer is one of the malignant tumors of digestive tract with high incidence and mortality worldwide,
surgery is still the primary treatment for esophageal cancer, enteral nutrition（EN）is the first choice for postoperative nutritional
support. After surgery, patients with esophageal cancer need to undergo a long time of EN support and gradually transition to oral
feeding. After 3 to 9 months, the new diet pattern is reconstructed, and enteral nutrition support becomes an important stage for most
patients to resume normal diet after surgery. Postoperative EN support in patients with esophageal cancer is prone to intestinal
intolerance. It hinders the smooth implementation of nutritional support treatment. Some patients are forced to stop nutritional therapy.
It has adverse effects on the quality of life and prognosis of patients. At present, there are no universally recognized and unified
evaluation indicators and evaluation tools at home and abroad, and most researchers design their own evaluation tools according to
the research objects, and the research objects are mainly in intensive care unit（ICU）, critically ill, premature infants and other infants,
and there is a lack of evaluation tools for intestinal intolerance in patients with esophageal cancer. The selection of effective assessment
indicators and tools can accurately and timely assess the occurrence and severity of intestinal intolerance, reduce the incidence of
intestinal intolerance, and provide a reference for the improvement of clinical nutritional support programs. The paper reviews the
assessment indicators and tools for intestinal intolerance in patients with postoperative EN support for esophageal cancer, aiming to
provide reference for clinical medical staff to accurately and effectively assess intestinal tolerance.
Abstract：Esophageal cancer is one of the malignant tumors of digestive tract with high incidence and mortality worldwide,
surgery is still the primary treatment for esophageal cancer, enteral nutrition（EN）is the first choice for postoperative nutritional
support. After surgery, patients with esophageal cancer need to undergo a long time of EN support and gradually transition to oral
feeding. After 3 to 9 months, the new diet pattern is reconstructed, and enteral nutrition support becomes an important stage for most
patients to resume normal diet after surgery. Postoperative EN support in patients with esophageal cancer is prone to intestinal
intolerance. It hinders the smooth implementation of nutritional support treatment. Some patients are forced to stop nutritional therapy.
It has adverse effects on the quality of life and prognosis of patients. At present, there are no universally recognized and unified
evaluation indicators and evaluation tools at home and abroad, and most researchers design their own evaluation tools according to
the research objects, and the research objects are mainly in intensive care unit（ICU）, critically ill, premature infants and other infants,
and there is a lack of evaluation tools for intestinal intolerance in patients with esophageal cancer. The selection of effective assessment
indicators and tools can accurately and timely assess the occurrence and severity of intestinal intolerance, reduce the incidence of
intestinal intolerance, and provide a reference for the improvement of clinical nutritional support programs. The paper reviews the
assessment indicators and tools for intestinal intolerance in patients with postoperative EN support for esophageal cancer, aiming to
provide reference for clinical medical staff to accurately and effectively assess intestinal tolerance.
1张影，2姜桂春，1于玲. 食管癌患者术后肠道不耐受评价指标及工具应用[J]. 肿瘤代谢与营养电子杂志, 2021, 8(1): 6-10.
1Zhang Ying, 2Jiang Guichun, 1Yu Ling. Research progress on evaluation indexes and application of evaluation tools for postoperative intestinal intolerance in patients
with esophageal cancer. Electron J Metab Nutr Cancer, 2021, 8(1): 6-10.
